Evolus, Inc. (NASDAQ:EOLS - Get Free Report) traded down 9.6% on Monday . The stock traded as low as $12.56 and last traded at $12.28. 206,913 shares were traded during trading, a decline of 65% from the average session volume of 592,049 shares. The stock had previously closed at $13.58.
Analyst Ratings Changes
Several research analysts recently issued reports on EOLS shares. Barclays raised their target price on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $27.00 price objective on shares of Evolus in a research note on Wednesday, March 5th.
View Our Latest Stock Report on Evolus
Evolus Price Performance
The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a 50 day simple moving average of $13.10 and a 200-day simple moving average of $14.00. The firm has a market cap of $830.06 million, a PE ratio of -14.34 and a beta of 1.28.
Institutional Trading of Evolus
Several hedge funds have recently modified their holdings of the company. Tri Locum Partners LP purchased a new position in Evolus during the 4th quarter worth approximately $8,198,000. Gilder Gagnon Howe & Co. LLC increased its holdings in shares of Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock valued at $7,753,000 after purchasing an additional 520,859 shares during the last quarter. Caligan Partners LP raised its stake in Evolus by 22.7% during the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after purchasing an additional 498,900 shares during the period. Allostery Investments LP purchased a new stake in Evolus in the fourth quarter valued at approximately $4,760,000. Finally, Altium Capital Management LLC lifted its position in shares of Evolus by 93.0% during the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock worth $7,562,000 after purchasing an additional 330,000 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
